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The article that appears in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology by Fryirs et al provides an important putative link between HDL components, especially its major apolipoproteins (apoproteins) apoA-I and apoA-II, and insulin secretion by ␤-cells. Over the last 5 years, there have been a number of studies that point to the role of ␤-cell cholesterol homeostasis on insulin secretion. Cholesterol homeostasis is dependent on the uptake of cholesterol by the LDL receptor, endogenous cholesterol biosynthesis, and cholesterol efflux via ATP-binding cassette transporter subfamily A1 (ABCA1) and related transporters. Hayden and coworkers have studied ␤-cell-specific ABCA1 knockout mice. 3, 4 The ␤-cells from these mice accumulate total and free cholesterol, and insulin secretion is impaired on glucose stimulation without significant changes in insulin mRNA, suggesting that cholesterol accumulation interferes with insulin exocytosis. Glucose tolerance is reduced in these animals without peripheral insulin resistance. Interestingly there was no impairment in basal insulin secretion in these deficient cells, but in these experiments, isolated islets were incubated in buffer without addition of apolipoproteins. Patients with loss of function mutations in ABCA1 exhibit impaired glucose tolerance. 5 Other approaches to the modification of islet cholesterol homeostasis, eg, in apoE-deficient mice or incubation with methyl-␤-cyclodextrin also influence insulin secretion. 6 The inhibition of endogenous cholesterol synthesis also impairs insulin secretion by both unstimulated and stimulated islets. 7 Taken together, these data suggest that insulin secretory capacity is sensitive to a fairly finely regulated cholesterol content in ␤-cells.
ABCA1 interacts with extracellular amphipathic apolipoproteins to initiate efflux of cholesterol from cells. Most studies have been performed with apoA-I but, this can be mediated also by apoA-II. The latter apoprotein competes very effectively for the binding of apoA-I to ABCA1 expressing cells. 8 In the study reported in this issue, 9 isolated ␤-cells, either MIN6 cells or primary rat ␤-cells, responded to either lipid-free apoA-I or apoA-II, as well as discoid reconstituted HDL containing either of the 2 apoproteins with an increase in insulin secretion ( Figure) . This was observed under basal conditions (2.8 mmol/L glucose) or with glucose stimulation (25 mmol/ L). The response was rapid, being demonstrable as early as 15 minutes under basal conditions and 5 minutes on glucose stimulation. Also, human HDL at physiological concentration increased insulin secretion under basal conditions. The mechanisms by which lipid-free apoprotein promotes insulin secretion is different under basal and glucose-stimulated conditions. Under basal conditions, lipid-free apoprotein accentuates insulin secretion by a process that is independent of the potassium ATP channel and cell glucose metabolism (low temperature). This is not the case for the glucose stimulated secretion. However, under both basal and stimulated conditions, extracellular calcium and intracellular calcium homeostasis is required for optimal insulin secretion promoted by the 2 apoproteins.
The optimal response to lipid-free apoprotein-stimulating effect in this cell culture system is dependent on the availability of the transporters/receptors ABCA1, scavenger receptor B1, and for discoid reconstituted HDL on ABCG1. This might lead one to expect that an influence on cholesterol homeostasis is involved in the stimulated insulin secretion. However, no change in total cholesterol or free cholesterol was noted in the cells when insulin secretion was stimulated either under basal or high-glucose conditions. Given the molecules involved, this is somewhat surprising, although a change in the distribution of cholesterol among cell membranes and cellular compartments cannot be excluded. It has been found recently that the engagement of ABCA1 by apoproteins activates Janus kinase 2 and signal transducer and activator of transcription 3 phosphorylation, 10 independent of effects on cholesterol homeostasis, which influences cytokine production and perhaps apoptosis. Lipoproteins may modulate apoptosis in ␤-cells. 11 No apoptosis was noted in the MIN6 cells incubated for 16 hours with the lipid-free apoproteins. However, activation of Janus kinase 2 and signal transducer and activator of transcription 3 phosphorylation, mediated by engagement of the leptin receptor, reduces insulin secretion. 12 Also, apoA-I may promote cAMP forma-tion. 13 Whether these signaling pathways participate in the stimulation of insulin secretion as studied in this article remains to be established.
There is a suggestion that the apoA-I and apoA-II stimulation of insulin secretion may have different quantitative dependencies on the intracellular calcium balance, especially in glucose-stimulated cells. Preincubation with EDTA eliminates the stimulatory effect of apoA-I but not apoA-II. A similar trend is seen when intracellular calcium redistribution is inhibited. This highlights our relative ignorance of the physiological functions of apoA-II. In addition, the physiological existence of lipid-free apoA-II in tissue fluid and plasma is uncertain, since this is a highly hydrophobic apolipoprotein.
The insulin resistance associated with metabolic syndrome and low HDL may progress to frank diabetes. Is it possible that apoprotein-stimulated insulin secretion is attenuated during this progression? First, the stimulation of insulin secretion is apoprotein concentration dependent over a physiologically relevant range. So with low HDL in vivo, especially if this HDL is dysfunctional, as is likely the case in diabetes and the metabolic syndrome, the optimal cofactors for insulin secretion and compensatory function of the ␤-cell may be limited. Furthermore, in the prediabetic and diabetic state, many proteins may become glycated or modified by carbonyls derived from carbohydrate oxidation, such as glycolaldehyde, glyoxal, and methylglyoxal. ApoA-I modified by these carbonyls is still able to mediate ABCA1-dependent cholesterol efflux. 14 However, these carbohydrate-derived aldehydes have the capacity to influence ABCA1 function and particularly stabilization so that the functioning of this interacting couple of proteins may well be impaired in diabetes or prediabetes. 15 Thus, it is clear that the interaction of HDL and its constituent apoproteins with ␤-cell ABC transporters yields a complex series of responses affecting insulin production that may well be pathophysiologically relevant. The precise mechanisms of these interactions and how they signal to influence ␤-cell function have yet to be explored in detail. The article by Fryirs et al should certainly stimulate a good deal of further work to elucidate in detail the mechanisms by which HDL interacts with and modulates the function of the ␤-cell.
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Figure.
ApoA-I and apoA-II, as lipid-free proteins and in reconstituted HDL (rHDL), stimulate insulin secretion from pancreatic ␤-cells under basal and glucose-stimulated conditions. The apoprotein-stimulated secretion is dependent on their interaction with ABCA1, scavenger receptor B1, or ABCG1. Whether or which signaling pathways are involved is not clear. Increased cellular cholesterol inhibits insulin secretion via inhibition of glucokinase activity, preventing the phosphorylation of glucose, and perhaps also by the inhibition of signaling pathways initiated by the interaction of the apoproteins with the transporters or receptor on the cell surface.
